07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

University Health Network, Sernova deal

The University Health Network granted Sernova exclusive, worldwide rights to technology related to developing stem cells into glucose-responsive therapeutic cells to treat insulin-dependent diabetes. Sernova plans to use the cells with its Cell Pouch,...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

Sernova, Massachusetts General Hospital, JDRF deal

Sernova and the hospital partnered to develop a treatment for Type I diabetes. The partnership includes $150,000 in funding from the JDRF. The deal will incorporate an immune protectant technology developed at the hospital with...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Cell Pouch: Phase I/II data

Data from the first 2 patients in an open-label, Canadian Phase I/II trial showed that Cell Pouch implanted 2-12 weeks before transplantation of human donor islets was safe. Following islet transplantation, Sernova said the islet...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Medicyte, Sernova deal

The companies signed a material transfer agreement to jointly evaluate the use of Medicyte's upcyte technology in Sernova's Cell Pouch System to treat hemophilia A. The companies have also signed a non-binding term sheet...
07:00 , May 28, 2012 |  BioCentury  |  Product Development

Islet defense

Sernova Corp. is developing its Sertolin cell technology and Cell Pouch System device to provide an immune-privileged, vascularized environment for donor islet cells to produce insulin in insulin-dependent diabetes patients. The approach is intended to...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

Cell Pouch: Phase I/II started

Sernova began an open-label, Canadian Phase I/II trial to evaluate Cell Pouch implanted 2-12 weeks before transplantation of donor human islets in up to 20 patients with insulin-dependent diabetes undergoing allograft pancreatic islet transplantation. Patients...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Sernova, University of Alberta Hospital deal

Sernova partnered with the hospital's Clinical Islet Transplant Program to develop a next generation version of Sernova's Cell Pouch System for islet cell transplantation. Sernova will provide funding to the hospital for studies of...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Sernova preclinical data

In cynomolgus monkeys, implantation of Sernova's Cell Pouch System led to no skin irritation, inflammation or infections through 8 weeks. Additionally, the company said the cell pouches were "well-incorporated" with collagen and tissues, had "well-established"...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

Sernova preclinical data

Diabetic pigs receiving autologous islet cell transplantation using Sernova's Cell Pouch System device achieved long-term glucose normalization and were C-peptide positive, an indication of insulin-producing islet function. Additionally, long-term insulin independence was successfully achieved with...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Sernova preclinical data

In diabetic rats, porcine islet cells co-transplanted with porcine Sertoli cells significantly inhibited IgG immune responses and induced long-term insulin production at 70 and 180 days post-implantation compared with porcine islets alone, which were destroyed...